They have a binary event coming up in January (Phase III HEAT study). Their chemo delivery mechanism might revolutionalize the way we first-line treat MANY forms of cancer. If the study is successful end meets its endpoints, the stock will soar. If not, and it will tumble.
The only sure thing about biopharma investing is that there's no such thing as a sure thing. At any given moment all is lost. The rewards are great...the risks even greater. I question if there is really such a thing as DD in this regard. Most of the movement in these names is headline or rumor driven. Anyone plunking down cash prior to phase III results being announced is gambling. Buyer beware.